
BFRA
Healthcare · Pharmaceuticals · $75.7M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2021
EPS trend, 90 days to now · +8.7% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 17, 2021 | After the close | -0.15 | -0.23 | -48.3% |
| Aug 19, 2021 | After the close | -0.23 | -0.16 | +29.3% |
| Apr 12, 2021 | After the close | -0.07 | -0.29 | -282.6% |
| Jan 5, 2021 | Time not confirmed | -0.13 | -0.33 | -152.0% |
| Nov 11, 2020 | After the close | -0.18 | -0.28 | -57.0% |
| Aug 27, 2020 | Before the open | 0.03 | 0.05 | +59.8% |
| Apr 20, 2020 | After the close | -0.13 | -0.22 | -63.3% |
| Dec 31, 2019 | Time not confirmed | -0.11 | -0.22 | -100.0% |
| Nov 19, 2019 | Before the open | -0.33 | -0.58 | -74.5% |
| Aug 27, 2019 | Before the open | -0.23 | 0.58 | +351.1% |
| Apr 29, 2019 | Before the open | 0.14 | 0.18 | +27.7% |
| Jan 22, 2019 | Before the open | -0.13 | 0.18 | +238.5% |
| Nov 16, 2018 | Before the open | -0.20 |
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers…
| -0.23 |
| -14.8% |
| Aug 31, 2018 | Before the open | -0.24 | -0.23 | +1.8% |
| Apr 28, 2018 | Time not confirmed | -0.21 | -0.10 | +53.9% |